Azione KRRO KORRO BIO, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Korro Bio, Inc.

Azioni

KRRO

US5009461089

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 26/04/2024 		Variaz. 5gg Var. 1 gen.
62,93 USD +7,52% Grafico intraday di Korro Bio, Inc. -5,71% +31,30%
24/04 L'insider di Korro Bio ha acquistato azioni per un valore di 999.992 dollari, secondo un recente deposito SEC MT
24/04 L'insider di Korro Bio ha acquistato azioni per un valore di 999.992 dollari, secondo un recente deposito SEC MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.
Korro Announces $70 Million Private Placement
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
North American Morning Briefing : Stocks Struggle After New Records
North American Morning Briefing : Inflation -2-
Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing
Korro to Present at the TD Cowen 44th Annual Health Care Conference
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione KRRO
  4. Notizie Korro Bio, Inc.
  5. Altre lingue